Zantac Heartburn Medication
In October 2019, a class-action lawsuit was filed against Sanofi-Aventis U.S., Sanofi US Services, Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals for allegedly failing to disclose that the over-the-counter heartburn medication Zantac exposes users to unsafe levels of the carcinogen N-Nitrosodimethylamine (NDMA). (Dimesky et al v. Sanofi-Aventis U.S., LLC, Sanofi US Services Inc., Chattem, Inc., and Boehringer Ingelheim Pharmaceuticals, Inc., Case No. 19-cv-1517, D. CT.)
Class-Action Tracker
The Latest
Consumer Cellular
TINA.org uncovers the limits of this carrier’s “unlimited” data plans.
There Should Be a Price to Pay for Knowingly Lying to Consumers
Why TINA.org wants the Supreme Court to address proof of harm in Lanham Act cases.
TINA.org Action Sheds Light on SunPowerLED’s False Endorsement Claims
Letters alert agencies and organizations to company’s improper marketing.
VIN History USA’s ‘Free’ VIN Report
TINA.org discovers some roadblocks to unlocking this purportedly free offer.
Will the MLM Industry Fix Its Earnings Claims Problem?
New research points to “no.”